Plain-English translation of NCT07048197 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called for people with rheumatoid arthritis or Sjögren's disease that hasn't improved with standard medicines. The medication works by using your own immune cells, which are collected, modified in a laboratory, and then given back to you as a single infusion. Researchers want to understand how safe this treatment is, how it works in your body, and whether it can reduce symptoms and disease activity.
Some people with rheumatoid arthritis or Sjögren's disease don't improve enough with traditional treatments, and their conditions can seriously affect their organs and quality of life. This trial exists to explore whether this new cell-based approach could offer hope to patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive a single infusion of the new medication at the study clinic. Before the infusion, your cells will be collected through a process similar to a blood draw, sent to a laboratory to be modified, and then prepared for your infusion. After receiving the treatment, you will have regular clinic visits and blood tests so the research team can monitor how the medication is working in your body and watch for any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
France
Germany